FHTX · Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc (FHTX)
What's happening
- FHTX is up 1.24% today, trading at $2.04. — Live quote
- Volume today (64,931) is well below its 3-month average of 588,250. (Finnhub fundamentals)
- Reports earnings on 2026-11-10 (before market open), 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.10 actual vs. $-0.26 estimated (+61.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (16 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $350.9M | $327.6M | $311.0M | $302.3M | $229.5M |
| P/E | -5.77 | -4.52 | -4.33 | -3.83 | -2.67 |
| Price/Sales | 10.01 | 13.14 | 10.55 | 10.72 | 8.93 |
| Price/Book | -4.33 | -4.29 | -3.47 | -3.94 | -3.72 |
| EV/Revenue | 8.07 | 9.62 | 7.52 | 8.15 | 6.55 |
| EV/EBITDA | -4.18 | -2.95 | -2.67 | — | — |
| ROE | 75.09% | 94.88% | 80.02% | 102.89% | 139.41% |
| ROA | -29.92% | -32.63% | -35.00% | -34.86% | -33.23% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 112.7% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-01; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -175.8%. Finnhub fundamentals ↗
- Trailing 52-week price return is -50.2%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on FHTX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.1M | $3.3M | $8.2M | $7.6M | $6.0M | $7.8M | $6.9M | $5.0M |
| Operating income | -$8.8M | -$21.6M | -$18.5M | -$21.1M | -$22.9M | -$23.9M | -$26.6M | -$28.2M |
| Net income | -$7.2M | -$19.9M | -$15.8M | -$17.9M | -$18.8M | -$19.1M | -$23.0M | -$25.0M |
| EPS (diluted) | $-0.10 | $-0.29 | $-0.25 | $-0.28 | $-0.30 | $-0.31 | $-0.45 | $-0.59 |
| EPS (basic) | $-0.10 | $-0.29 | $-0.25 | $-0.28 | $-0.30 | $-0.31 | $-0.45 | $-0.59 |
| Operating margin | -$55 | -$660 | -$227 | -$279 | -$385 | -$305 | -$387 | -$558 |
| Net margin | -$45 | -$608 | -$194 | -$237 | -$316 | -$245 | -$334 | -$495 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $203.4M | $222.2M | $198.1M | $205.0M | $226.2M | $258.7M | $284.0M | $308.4M |
| Total liabilities | $284.4M | $298.6M | $306.6M | $294.6M | $302.9M | $320.3M | $329.5M | $336.7M |
| Stockholders' equity | -$81.0M | -$76.4M | -$108.5M | -$89.7M | -$76.7M | -$61.7M | -$45.5M | -$28.3M |
| Total current assets | $170.0M | $188.1M | $163.2M | $184.1M | $203.8M | $225.4M | $249.6M | $271.2M |
| Total current liabilities | $50.6M | $64.4M | $59.7M | $85.1M | $77.8M | $71.3M | $67.0M | $56.8M |
| Cash & equivalents | $68.1M | $87.7M | $80.9M | $89.3M | $72.6M | $61.0M | $55.5M | $57.7M |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Other non-current assets | $3.0K | $3.0K | $4.0K | $5.0K | $6.0K | $24.0K | $68.0K | $848.0K |
| Accounts payable | $3.2M | $3.3M | $4.3M | $3.2M | $3.3M | $4.1M | $3.8M | $3.5M |
| Accrued liabilities | $8.0M | $6.9M | $11.4M | $9.8M | $8.6M | $6.5M | $8.5M | $11.2M |
| Deferred revenue (current) | $36.6M | $52.3M | $43.2M | $65.3M | $59.7M | $51.7M | $45.6M | $33.4M |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $350.0K | $453.0K | $556.0K | $656.0K | $757.0K | $856.0K | $0 | — |
| Common stock & paid-in capital | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K |
| Retained earnings | -$659.5M | -$652.3M | -$632.5M | -$610.8M | -$595.0M | -$577.0M | -$558.2M | -$538.7M |
| Accumulated other comprehensive income (loss) | -$134.0K | -$133.0K | $24.0K | $24.0K | -$44.0K | $14.0K | $135.0K | $360.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$17.8M | -$25.3M | -$22.3M | -$18.9M | -$21.0M | -$24.0M | -$24.5M | -$21.0M |
| Investing cash flow | -$3.0M | -$17.7M | $13.2M | $35.6M | $33.8M | $29.4M | $22.3M | -$61.3M |
| Financing cash flow | -$22.0K | $49.8M | $581.0K | $49.0K | $254.0K | $139.0K | $4.0K | $1.1M |
| Free cash flow | -$17.9M | -$25.3M | -$22.3M | -$18.9M | -$21.0M | -$24.0M | -$25.0M | -$21.3M |
| Capital expenditures | $50.0K | $0 | $0 | $0 | $22.0K | $28.0K | $479.0K | $309.0K |
| Depreciation & amortization | $200.0K | $238.0K | $2.5M | $900.0K | $900.0K | $827.0K | $2.3M | $700.0K |
| Share-based compensation | $2.5M | $2.4M | $7.7M | $2.7M | $2.7M | $2.7M | $8.7M | $3.0M |
| Change in accounts payable | -$69.0K | -$990.0K | $1.1M | -$110.0K | -$747.0K | $284.0K | $334.0K | -$1.4M |
| Purchases of investments | $37.1M | $66.9M | $34.0M | $4.0M | $42.1M | $51.1M | $39.6M | $124.5M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $30.9M | $22.6M | $34.2M | $19.2M | $1.3M |
| Operating income | -$86.4M | -$102.7M | -$107.9M | -$117.1M | -$100.7M |
| Net income | -$74.3M | -$86.6M | -$98.4M | -$108.9M | -$101.3M |
| EPS (diluted) | $-1.18 | $-1.58 | $-2.34 | $-2.62 | $-2.73 |
| EPS (basic) | $-1.18 | $-1.58 | $-2.34 | $-2.62 | $-2.73 |
| Operating margin | -$279 | -$454 | -$316 | -$609 | -$7.6K |
| Net margin | -$240 | -$383 | -$288 | -$566 | -$7.7K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $198.1M | $284.0M | $285.9M | $404.9M | $519.8M |
| Total liabilities | $306.6M | $329.5M | $363.1M | $404.8M | $422.9M |
| Stockholders' equity | -$108.5M | -$45.5M | -$77.2M | $112.0K | $96.9M |
| Total current assets | $163.2M | $249.6M | $240.2M | $351.4M | $459.6M |
| Total current liabilities | $59.7M | $67.0M | $58.4M | $55.2M | $48.7M |
| Cash & equivalents | $80.9M | $55.5M | $80.3M | $52.2M | $101.1M |
| Property, plant & equipment | — | — | — | — | — |
| Other non-current assets | $4.0K | $68.0K | $1.1M | $2.4M | $2.4M |
| Accounts payable | $4.3M | $3.8M | $6.3M | $5.4M | $3.8M |
| Accrued liabilities | $11.4M | $8.5M | $9.1M | $11.0M | $9.6M |
| Deferred revenue (current) | $43.2M | $45.6M | $34.5M | $32.8M | $28.3M |
| Short-term debt | — | — | — | — | — |
| Long-term debt | — | — | — | — | $0 |
| Other non-current liabilities | $556.0K | $0 | $0 | $29.0K | $143.0K |
| Common stock & paid-in capital | $6.0K | $6.0K | $4.0K | $4.0K | $4.0K |
| Retained earnings | -$632.5M | -$558.2M | -$471.6M | -$373.1M | -$264.3M |
| Accumulated other comprehensive income (loss) | $24.0K | $135.0K | -$826.0K | -$4.0M | -$10.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$86.1M | -$100.4M | -$118.1M | $193.6M | -$50.2M |
| Investing cash flow | $112.0M | -$29.9M | $144.4M | -$244.3M | $36.2M |
| Financing cash flow | $1.0M | $105.4M | $1.8M | $1.8M | $22.4M |
| Free cash flow | -$86.1M | -$101.3M | -$119.3M | $192.4M | -$53.6M |
| Capital expenditures | $50.0K | $906.0K | $1.2M | $1.2M | $3.3M |
| Depreciation & amortization | $3.3M | $3.1M | $3.5M | $3.3M | $3.2M |
| Share-based compensation | $10.4M | $11.9M | $16.2M | $14.3M | $8.4M |
| Change in accounts payable | $481.0K | -$2.5M | $846.0K | $1.6M | $135.0K |
| Purchases of investments | $131.2M | $261.5M | $73.9M | $409.3M | $100.0M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding FHTX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-04-09 to 2026-04-10
Recent transactions
- Most recent: GOTTSCHALK ADRIAN (Chief Executive Officer) — Gift of 59,208 shares on 2026-04-10.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| GOTTSCHALK ADRIAN | Chief Executive Officer | Gift | 2026-04-10 | 59,208 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-04-10 | GOTTSCHALK ADRIAN | Chief Executive Officer | Gift | 59,208 | $0.00 |
| 2026-04-10 | GOTTSCHALK ADRIAN | Chief Executive Officer | Gift | 59,208 | $0.00 |
| 2026-04-09 | GOTTSCHALK ADRIAN | Chief Executive Officer | Gift | 47,497 | $0.00 |
| 2026-04-09 | GOTTSCHALK ADRIAN | Chief Executive Officer | Gift | 47,497 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:19 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-01 | 8-K | 2026-09-25 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-06-25 | 4 | 2026-06-24 | View on SEC.gov → |
| 2026-06-25 | 4 | 2026-06-24 | View on SEC.gov → |
| 2026-06-25 | 4 | 2026-06-24 | View on SEC.gov → |
| 2026-06-25 | 4 | 2026-06-24 | View on SEC.gov → |
| 2026-06-25 | 4 | 2026-06-24 | View on SEC.gov → |
| 2026-06-25 | 4 | 2026-06-24 | View on SEC.gov → |
| 2026-06-25 | 4 | 2026-06-24 | View on SEC.gov → |
| 2026-06-25 | 4 | 2026-06-24 | View on SEC.gov → |
| 2026-06-25 | 4 | 2026-06-24 | View on SEC.gov → |
Recent news
Headlines about FHTX (Foghorn Therapeutics Inc.). Links open the publisher — we don’t host full articles.
-
Foghorn Therapeutics (FHTX) Stock Fair Value Moves Lower After Pipeline And Lilly Reset
Yahoo Finance · 2026-10-22 -
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
PR Newswire · 2026-10-15 -
Foghorn: Downgrade 'Sell' Eli Lilly Exit FHD-909 And Shift To Preclinical Assets
Seeking Alpha · 2026-10-06 -
FHTX Stock Extends Sell-Off After Lilly Collaboration Ends — Wedbush Slashes Target By 80%
Yahoo Finance · 2026-10-02 -
Foghorn extends losses as TD Cowen cuts on Lilly exit
Seeking Alpha · 2026-10-02 -
Sector Update: Healthcare Stocks Fall Late Afternoon
Yahoo Finance · 2026-10-01 -
Foghorn Stock Sinks as Lilly Scraps Cancer Deal, Forcing 40% Layoffs
Yahoo Finance · 2026-10-01 -
Top Midday Decliners
Yahoo Finance · 2026-10-01
No headlines in this category right now — try “All”.